[ad_1]
Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company specializing in the discovery and development of innovative protein therapeutics by immuno-oncology, announced today the departure of Dr. Sheila Gujrathi from the Board of Directors of Immuno-Oncology. the society. Dr. Gujrathi has been a member of the Five Prime Board of Directors since December 2015 and is stepping down from the Board to serve as President and Chief Executive Officer of Gossamer Bio, Inc., a biopharmaceutical company. which she co-founded in 2017. and which completed her IPO in February 2019.
Sheila has made many important contributions to the Five Primes Board of Directors. During her tenure, Five Prime benefited from Sheila's intellect, good judgment and pragmatic advice. We are very grateful for his services and the other directors join me in wishing him good luck, "said Aron Knickerbocker, CEO of Five Prime Therapeutics.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative protein therapies to improve the lives of patients with serious illnesses. Five Primes product candidates have innovative mechanisms of action and address patient populations in need of better treatments. The company focuses on the research and development of immuno-oncology and targeted cancer therapies, coupled with companion diagnoses, to identify the patients most likely to benefit from treatment with product candidates. Five Premiums. Five Prime has strategic partnerships with leading global pharmaceutical companies and offers promising product candidates in clinical and preclinical development. For more information, visit www.fiveprime.com or follow us on LinkedIn, Twitter and Facebook.
Caution regarding forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, 1995. Expressions such as may, anticipate, plan, anticipate, estimate, express intent or similar expressions events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on the expectations and badumptions of Five Prime as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Other factors that may cause actual results to differ from those expressed or implied by the forward-looking statements in this news release are discussed under "Five Premiums Deposits" at the Securities and Exchange Commission of the United States. United States, including the risk factors therein. Except as provided by law, Five Prime badumes no obligation to update the forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Source: Five Prime Therapeutics, Inc.
Media and investor contact
Martin Forrest
VP, investor
Corporate Relations and Communications
Five first treatments,
Inc.
415-365-5625
[email protected]
Source link
